- Trials with a EudraCT protocol (158)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
158 result(s) found for: Bacterial strain.
Displaying page 1 of 8.
EudraCT Number: 2008-007789-51 | Sponsor Protocol Number: B1971005(6108A1-2001-WW) | Start Date*: 2009-03-23 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µ... | |||||||||||||
Medical condition: The test is a vaccine. The subjects are healthy adolescents. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002972-95 | Sponsor Protocol Number: V72_74 | Start Date*: 2014-12-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: Phase 3b, Open label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults from 18 to 50 Y... | |||||||||||||
Medical condition: Meningococcal Group B disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001355-12 | Sponsor Protocol Number: LPS15198 | Start Date*: 2019-02-27 | |||||||||||
Sponsor Name:SANOFI-AVENTIS GROUPE | |||||||||||||
Full Title: Phase IV, randomized, double-blind, multicenter, placebo-controlled clinical trial to evaluate the efficacy and the safety of enterogermina (Bacillus clausii) in treating patients with small intest... | |||||||||||||
Medical condition: Small intestinal bacterial overgrowth (SIBO) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002454-78 | Sponsor Protocol Number: V72_62 | Start Date*: 2014-02-18 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | |||||||||||||
Full Title: A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine when administered to Immunoco... | |||||||||||||
Medical condition: Meningococcal Group B disease. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005815-25 | Sponsor Protocol Number: V72_59 | Start Date*: 2013-07-09 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | |||||||||||||
Full Title: A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-Risk Adu... | |||||||||||||
Medical condition: A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-Risk Adu... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000657-30 | Sponsor Protocol Number: V72_28E1 | Start Date*: 2013-05-30 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics s.r.l. | |||||||||||||
Full Title: A Phase IIIB, Open Label, Multi-Center Extension Study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in ... | |||||||||||||
Medical condition: A phase IIIB, Open Label, Multi Center extension study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001763-39 | Sponsor Protocol Number: MU1441 | Start Date*: 2015-09-09 |
Sponsor Name:Ardeypharm GmbH | ||
Full Title: E. coli Nissle 1917 - Suspension for infection prophylaxis | ||
Medical condition: Following viral and bacterial infections: - Acute upper respiratory tract infections (i.e. rhinopharyngitis, laryngitis, angina tonsillitis, tracheitis) - Acute lower respiratory tract infectio... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005128-12 | Sponsor Protocol Number: 208205 | Start Date*: 2018-06-11 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA | |||||||||||||
Full Title: A Phase II, Randomized, Open-label, Multicenter Study to Assess the Immunogenicity and Safety of GSK Meningococcal MenABCWY Vaccine, and of GSK Meningococcal Group B and MenACWY Conjugate Vaccines ... | |||||||||||||
Medical condition: Primary immunization against Neisseria meningitidis serogroups A, B, C, W-135, and Y. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003923-17 | Sponsor Protocol Number: SH600008 | Start Date*: 2023-01-26 | ||||||||||||||||
Sponsor Name:Sanofi Pasteur | ||||||||||||||||||
Full Title: Safety and Immunogenicity Study of Full Schedule (3-Dose of Shan6™) or Shan6™-Shan5®-Shan6™ Versus the Licensed Vaccine Shan5® With bOPV (bivalent oral polio vaccine) and IPV (inactivated poliomyel... | ||||||||||||||||||
Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004410-29 | Sponsor Protocol Number: V72P10 | Start Date*: 2014-10-27 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l | ||
Full Title: A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged ... | ||
Medical condition: Prophylaxis against invasive meningococcal disease | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-002451-15 | Sponsor Protocol Number: V102_15 | Start Date*: 2014-09-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA | |||||||||||||
Full Title: A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK... | |||||||||||||
Medical condition: The current study is designed to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those o... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002230-69 | Sponsor Protocol Number: V102_15E1 | Start Date*: 2016-10-31 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals S.A. | |||||||||||||
Full Title: A Phase 2b, Open-Label, Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 years After the last Meningococcal Vaccination in Study V102_15 and the Response ... | |||||||||||||
Medical condition: Meningococcal diseases | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004982-42 | Sponsor Protocol Number: 213171 | Start Date*: 2021-02-08 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologics SA (GSK) | |||||||||||||
Full Title: A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously... | |||||||||||||
Medical condition: Healthy volunteers (active immunization against invasive disease caused by N. meningitidis serogroups A, B, C, W and Y) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004531-36 | Sponsor Protocol Number: MU1646 | Start Date*: 2018-09-03 |
Sponsor Name:Ardeypharm GmbH | ||
Full Title: Escherichia coli strain Nissle 1917 - Suspension for treatment of patients with Clostridium difficile associated diarrhoea | ||
Medical condition: Clostridium difficile associated diarrhoea (CDAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-006209-83 | Sponsor Protocol Number: 2011/198/HP | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU - Hôpitaux de Rouen | |||||||||||||
Full Title: Evaluation of the Immune Response against Neisseria meningitidis B:14, P1-7,16 in subjects inoculated by MenBVac ® vaccine. | |||||||||||||
Medical condition: Immunogenic Study, in french children living in the region of Normandy, France, after vaccination for B:14:P1.7,16, to evaluate the longer-term persistence of antibodies against B:14P1.7,16. bacter... | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006268-27 | Sponsor Protocol Number: 2011/199/HP | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU - Hôpitaux de Rouen | |||||||||||||
Full Title: Evaluation of the Immune Response against Neisseria meningitidis B:14,P1-7,16 in subjects inoculated by MenBVac (R) vaccine. | |||||||||||||
Medical condition: Immunogenic Study, in french children living in the region of Normandy, France, after vaccination for B:14,P1-7,16 bacterial strain. | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002439-26 | Sponsor Protocol Number: 217744/100 | Start Date*: 2015-02-17 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: An open, multicentre, post-marketing surveillance (PMS) study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib vaccine administered at 3 and 4 months of age and ... | ||
Medical condition: Primary immunization of healthy infants against diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b diseases. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-004381-25 | Sponsor Protocol Number: 1608170 | Start Date*: 2017-11-24 | |||||||||||
Sponsor Name:CHU de Saint-Etienne | |||||||||||||
Full Title: Study of the impact of a targeted decolonization of S. aureus in persistent carriers on the occurrence of S. aureus infections in hemodialysis patients | |||||||||||||
Medical condition: Hemodialysis patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002427-15 | Sponsor Protocol Number: 105910 | Start Date*: 2015-06-01 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, partially double-blind clinical trial to evaluate the immu-nogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as co... | ||
Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis diseases and, if applicable, Haemophilus influenzae type b disease. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-003937-41 | Sponsor Protocol Number: V102_03E1 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:GSK Vaccines S.r.l | |||||||||||||
Full Title: Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Follow... | |||||||||||||
Medical condition: This study will evaluate the safety and immunogenicity of a booster dose of MenABCWY vaccine; either MenABCWY+OMV or MenABCWY+1/4OMV, administered to adolescent and young adults who previously rece... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
